 ALPHARETTA, Ga., Sept. 21, 2021 GLOBE NEWSWIRE -- Clearside Biomedical, Inc. NASDAQ:CLSD, a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today completion of dosing in Cohort 2 of OASIS, its ongoing Phase 12a clinical trial of CLS-AX axitinib injectable suspension in patients with neovascular age-related macular degeneration wet AMD. 